Sensirion to start production of SHT21 sensor

Published: 29-Mar-2010
Regulatory

Swiss manufacturer says it is the smallest digital humidity sensor in the world

Sensirion, a Swiss manufacturer of CMOS-based sensor components and systems, is to begin serial production of the SHT21 next month (April).

The SHT21 consists of a newly designed sensor chip encapsulated in a DFN 3-0 package. With this encapsulation the chip is completely over-moulded, except for the humidity sensing area. This reduces the component’s size to 3x3mm with a height of 1.1mm. The company says it also provides protection against condensation and harsh environments, therefore giving outstanding long-term stability.

Typical sensor accuracy is ±2% RH over 20–80% RH and ±0.3 °C over 25–42°C.

A scan path routine enables detailed sensor quality checking, while individual detailed tracking information on the chip can be read out by a simple command. Additionally, the SHT21 is reflow solderable without any degradation of sensor performance. The sensor is provided on tape and reel to facilitate trouble-free handling.

See more

You may also like

Regulatory

TurboFil offers industry-leading glove testing systems

Read more
Partnership with RAVONA delivers precision and compliance in aseptic environments

Trending Articles

  1. Piramal Pharma Solutions awards Riverview and Digwal for patient centricity Two sites recognised for innovative initiatives that put patients first
  2. Abzena advances immunogenicity risk assessment in biologic drug development New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins
  3. MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
  4. Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
  5. What to expect from a regulatory inspection NSF’s expert guide outlines key expectations, common pitfalls and strategies for lasting inspection readiness

You may also like

Regulatory

TurboFil offers industry-leading glove testing systems

Partnership with RAVONA delivers precision and compliance in aseptic environments
Manufacturing

How to execute a successful remediation strategy

NSF’s experts share guidance on building sustainable compliance and avoiding quick fixes
Manufacturing

How to optimise your quality culture and maturity for success

NSF outlines how aligning culture, leadership and systems can strengthen compliance and performance
Regulatory

Compliance ≠ Quality: why “meeting the standard” isn’t enough

In pharma manufacturing, regulatory compliance is non-negotiable. Whether it’s 21 CFR Part 11, EU Annex 11, or PIC/S PE-009, every manufacturer understands the need for validated systems, traceable records, and secure data
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Regulatory

Abzena advances immunogenicity risk assessment in biologic drug development

New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins
Regulatory

Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I

Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
Subscribe now